PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-89.95%
Negative EBIT growth while CRVO is at 9.71%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-95.43%
Negative operating income growth while CRVO is at 9.71%. Joel Greenblatt would press for urgent turnaround measures.
-134.36%
Negative net income growth while CRVO stands at 0.28%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-134.21%
Negative EPS growth while CRVO is at 3.84%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-134.21%
Negative diluted EPS growth while CRVO is at 3.84%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.82%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-141.82%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.42%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-31.42%
Negative 5Y OCF/share CAGR while CRVO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-183.28%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
1.36%
10Y net income/share CAGR of 1.36% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
1.36%
Positive 5Y CAGR while CRVO is negative. John Neff might view this as a strong mid-term relative advantage.
-52.35%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.38%
Negative 3Y equity/share growth while CRVO is at 45353.73%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.57%
Negative asset growth while CRVO invests at 2.35%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-12.67%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-28.84%
We’re deleveraging while CRVO stands at 2.18%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
60.35%
We expand SG&A while CRVO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.